Melanoma News and Research

Latest Melanoma News and Research

Novel combination therapy effective at treating patients with skin metastases

In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown.

12 Aug 2015

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Sorrento Therapeutics, Inc. announced today that it as well as its wholly-owned subsidiary TNK Therapeutics, Inc. have entered into a binding term sheet to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technologies Corp. and FetoLumina Technologies Corp., two privately-held sister biotechnology companies in Los Angeles, California.

11 Aug 2015

SCCA Proton Therapy Center makes advanced radiation therapy accessible to patients with ocular melanoma

For most the ability to see is often taken for granted. But for the thousands diagnosed with ocular melanoma, the fear of losing their eyesight or even worse, their lives, is an all too real possibility. Ocular melanoma is seen as a rare form of cancer, with approximately two thousand new diagnoses per year.

11 Aug 2015

Researchers create new cell screening method for immunotherapy cancer treatments

Researchers have created a new method for screening cells used in immunotherapy cancer treatments, allowing high-performing immune system cells to be studied in isolation and potentially expanding the number of patients for whom the breakthrough treatment proves successful.

11 Aug 2015

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced today the winners of the 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research.

10 Aug 2015

Discovery may lead to new ways to diagnose, treat brain cancer

Researchers at the Virginia Bioinformatics Institute have uncovered a link between the genomes of cells originating in the neural crest and development of tumors — a discovery that could lead to new ways to diagnose and treat cancer.

6 Aug 2015

Penn researchers identify major genetic factor that keeps moles in non-cancerous, no-growth state

Moles are benign tumors found on the skin of almost every adult. Scientists have known for years that a mutation in the BRAF gene makes them start growing, but until now haven't understood why they stop. Now, researchers from the Perelman School of Medicine at the University of Pennsylvania have identified a major genetic factor that keeps moles in their usual non-cancerous, no-growth state.

6 Aug 2015

Delcath Systems achieves record quarterly product revenue in Q2 2015

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2015.

5 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.

4 Aug 2015

Soldiers returning from combat missions in Iraq and Afghanistan at increased risk of skin cancer

Soldiers who served in the glaring desert sunlight of Iraq and Afghanistan returned home with an increased risk of skin cancer, due not only to the desert climate, but also a lack of sun protection, Vanderbilt dermatologist Jennifer Powers, M.D., reports in a study published recently in the Journal of Investigative Dermatology.

4 Aug 2015

New Tel Aviv University study sheds light on precise trigger of deadly melanoma

Skin cancer is the most common of all cancers, and melanoma, which accounts for 2% of skin cancer cases, is responsible for nearly all skin cancer deaths. Melanoma rates in the US have been rising rapidly over the last 30 years, and although scientists have managed to identify key risk factors, melanoma's modus operandi has eluded the world of medical research.

4 Aug 2015

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

The BRCA gene encodes for the BRCA proteins, BRCA1 and BRCA2. These proteins are very important in repairing DNA, which they do by correcting double-stranded breaks.

2 Aug 2015

One sunburn increases risk of skin cancer by 50%

Everybody's got a story about that "one bad burn" - the time you fell asleep next to the pool and tattooed a white handprint on your lobster-red chest, or forgot to pack the sunscreen while hiking a Colorado 14er.

30 Jul 2015

World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced that the World Health Organization's International Nonproprietary Name group has accepted the proposed generic name "piclidenoson" for its lead drug candidate, CF101.

29 Jul 2015

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

Yale researchers confirm NF1 gene as major player in development of skin cancer

A multidisciplinary team at Yale, led by Yale Cancer Center members, has defined a subgroup of genetic mutations that are present in a significant number of melanoma skin cancer cases. Their findings shed light on an important mutation in this deadly disease, and may lead to more targeted anti-cancer therapies.

28 Jul 2015

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

25 Jul 2015

Genetic variation influences survival in patients with multiple myeloma

As part of a multi-institutional effort, researchers with Huntsman Cancer Institute at the University of Utah have found that multiple myeloma patients with a genetic variation in the gene FOPNL die on average 1-3 years sooner than patients without it.

23 Jul 2015

Melanoma News and Research

Latest Melanoma News and Research

Novel combination therapy effective at treating patients with skin metastases

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

SCCA Proton Therapy Center makes advanced radiation therapy accessible to patients with ocular melanoma

Researchers create new cell screening method for immunotherapy cancer treatments

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

Discovery may lead to new ways to diagnose, treat brain cancer

Penn researchers identify major genetic factor that keeps moles in non-cancerous, no-growth state

Delcath Systems achieves record quarterly product revenue in Q2 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soldiers returning from combat missions in Iraq and Afghanistan at increased risk of skin cancer

New Tel Aviv University study sheds light on precise trigger of deadly melanoma

Array Biopharma reports strong fourth quarter and full year 2015 financial results

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

One sunburn increases risk of skin cancer by 50%

World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

Yale researchers confirm NF1 gene as major player in development of skin cancer

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Genetic variation influences survival in patients with multiple myeloma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in